SequelSEC

Aurinia Pharmaceuticals Inc. AUPH

Pharmaceutical Preparations · CIK 0001600620 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$83.22M
Fiscal year ended 2026-06-30
Operating income
$46.34M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Aurinia Pharmaceuticals Inc. (AUPH) reported revenue of $83.22M and net income of $37.41M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Aurinia Pharmaceuticals Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Aurinia Pharmaceuticals Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$83.22M$77.70M$77.11M$73.47M$70.01M$62.46M$59.87M$67.77M$57.19M$50.30M
Cost of revenue$6.56M$6.50M$8.80M$8.18M$7.12M$8.57M$5.55M$6.04M$8.91M$7.75M
Gross profit$76.66M$71.20M$68.32MUnavailable$62.89M$53.89M$54.32MUnavailableUnavailableUnavailable
Operating income$46.34M$41.42M$33.24M$29.74M$20.08M$21.85M-$1.67M$11.75M-$1.51M-$13.25M
Net income$37.41M$34.36M$210.79M$31.55M$21.51M$23.34M$1.43M$14.35M$722.00K-$10.75M
Research & development$13.05M$7.47M$10.90M$8.44M$7.43M$5.74M$8.11M$3.05M$4.08M$5.55M
Weighted-average diluted sharesshares 133.53Mshares 137.64MUnavailableshares 136.01Mshares 137.53Mshares 143.20MUnavailableshares 145.65Mshares 144.11Mshares 144.01M
Pretax income$48.79M$43.92M$35.69M$31.96M$22.16M$24.35M$1.17M$14.81M$1.48M-$10.01M
Income tax expense$11.37M$9.57M-$175.10M$411.00K$643.00K$1.00M-$256.00K$457.00K$756.00K$739.00K
Diluted EPS$0.28$0.25$1.53$0.23$0.16$0.16$0.01$0.10$0.01$-0.07
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$23.51M$22.03M$29.26M$26.18M$26.02M$20.34M$37.03M$42.37M$44.93M$47.70M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Aurinia Pharmaceuticals Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$179.73M$40.75M$80.16M$72.89M$52.91M$66.11M$83.40M$36.63M$33.26M$63.91M
Total assets$792.26M$724.00M$751.59M$527.53M$502.56M$504.85M$550.64M$549.36M$523.53M$516.63M
Current assets$541.32M$480.24M$491.97M$438.74M$408.97M$405.76M$446.60M$440.46M$409.67M$398.22M
Total liabilities$177.40M$156.37M$170.26M$161.76M$167.26M$154.66M$173.17M$161.36M$158.91M$157.16M
Current liabilities$99.89M$86.56M$93.72M$76.22M$78.27M$68.41M$97.76M$78.61M$76.90M$71.05M
Total equity incl. NCI$614.86M$567.63M$581.33M$365.77M$335.30M$350.19M$377.48M$388.00M$364.62M$359.48M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$45.15M$46.41M$45.69M$44.79M$46.50M$46.20M$39.23M$38.71M$38.85M$39.76M
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.74M$2.66M$3.31M$2.21M$3.31M$4.22M$5.19MUnavailableUnavailableUnavailable

Cash flow

Aurinia Pharmaceuticals Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow$52.57M$32.56M$45.67M$44.45M$44.24M$1.30M$30.11M$17.03M$15.84M-$18.60M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow$81.45M-$18.08M-$36.76M-$13.77M-$13.27M$31.03M$39.22M-$10.57M-$38.62M$49.23M
Financing cash flow$4.81M-$53.68M-$1.89M-$10.49M-$44.39M-$49.34M-$23.05M-$2.72M-$8.27M-$15.05M
Net change in cash$138.82M-$39.20M$7.02M$20.19M-$13.43M-$17.00M$46.29M$3.74M-$31.05M$15.58M
Stock-based compensation$2.84M-$866.00K$6.73M$5.92M$5.44M-$3.41M$8.95M$8.33M$8.59M$5.74M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$38.72M$36.16M$0$8.67M$42.56M$46.92M$21.80M$0$6.13M$12.30M
Depreciation & amortization$4.83M$4.82M$4.86M$4.86M$4.86M$4.86M$4.86M$4.89M$4.84M$4.85M

Derived

Aurinia Pharmaceuticals Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross margin92.1%91.6%88.6%Unavailable89.8%86.3%90.7%UnavailableUnavailableUnavailable
Operating margin55.7%53.3%43.1%40.5%28.7%35.0%-2.8%17.3%-2.6%-26.3%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue3.4%-1.1%8.7%Unavailable7.8%-5.5%14.9%UnavailableUnavailableUnavailable
Current ratio5.42x5.55x5.25x5.76x5.23x5.93x4.57x5.60x5.33x5.60x
Revenue YoY growth18.9%24.4%28.8%8.4%22.4%24.2%32.8%24.3%37.8%46.2%
Net margin45.0%Unavailable273.4%42.9%30.7%Unavailable2.4%21.2%1.3%-21.4%
R&D / revenue15.7%9.6%14.1%Unavailable10.6%9.2%13.5%UnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate23.3%21.8%-490.6%1.3%2.9%4.1%-21.8%3.1%51.2%Unavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AUPH in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-07-31View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

Reconciliation checks needing review

10 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2025-09-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-09-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-06-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-03-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-09-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-06-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-03-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2022-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2022-09-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.